SCHEMBL803947

SCHEMBL803947

CC(C)(C)OC(=O)NC1CCc2ccc(C(=O)NCCC3CCN(c4ccncc4)CC3)cc21

nearest known ligand 0.48

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
F10 P00742 11/20 0.48
BDKRB1 P46663 8/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL784561 0.85 BDKRB1 (0.42) F10BDKRB1
SCHEMBL784683 0.85 BDKRB1 (0.43) F10BDKRB1
SCHEMBL784501 0.85 BDKRB1 (0.43) F10BDKRB1
SCHEMBL785163 0.84 BDKRB1 (0.42) F10BDKRB1
SCHEMBL785224 0.84 BDKRB1 (0.44) F10BDKRB1
SCHEMBL784228 0.82 BDKRB1 (0.48) F10BDKRB1
SCHEMBL783741 0.82 BDKRB1 (0.59) F10BDKRB1
SCHEMBL785686 0.82 BDKRB1 (0.59) F10BDKRB1
SCHEMBL785218 0.82 GPR119 (0.39) F10
SCHEMBL785217 0.82 GPR119 (0.39) F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 F10 524/4885BDKRB1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.